Brazilian study maps HER2 in Women's cancers to guide future treatments

NCT ID NCT07101081

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 5 times

Summary

This study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how common HER2-high cancers are in Brazil, which could help doctors decide who might benefit from HER2-targeted drugs in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help identify which patients with gynecological cancers might benefit from HER2-targeted therapies in the future.
What could go wrong: This is an observational study, not a treatment trial. It only measures HER2 levels and does not test any drug, so it cannot directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer endometrial cancer female reproductive organ cancer ovarian cancer vaginal cancer vulva cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GYNAECOLOGICAL CANCERS

Contacts and locations

Locations

Research Site
RECRUITING

São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.